| Patents for A61K 48 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy (86,964) |
|---|
| 01/11/2001 | WO2001002578A1 Global regulators of bacterial pathogenic genes; bacterial autoinducer inactivation protein, as targets for engineering disease resistance |
| 01/11/2001 | WO2001002570A1 Delivery of trefoil peptides |
| 01/11/2001 | WO2001002561A2 Mammalian calcium channels and related probes, cell lines and methods |
| 01/11/2001 | WO2001002560A1 Novel genes and their use in the modulation of obesity, diabetes and energy imbalance |
| 01/11/2001 | WO2001002559A1 Compositions and methods for enhanced sensitivity and specificity of nucleic acid synthesis |
| 01/11/2001 | WO2001002557A1 Neurotrophic factor receptor |
| 01/11/2001 | WO2001002556A2 Agents for the diagnosis, prognosis and treatment of malignant diseases |
| 01/11/2001 | WO2001002553A2 Dna binding protein and sequence as insulators having specific enhancer blocking activity for regulation of gene expression |
| 01/11/2001 | WO2001002550A2 Cell death related drug targets in yeast and fungi |
| 01/11/2001 | WO2001002540A2 Adenoviral vectors for treating disease |
| 01/11/2001 | WO2001002439A1 Neovascular-targeted immunoconjugates |
| 01/11/2001 | WO2001002434A1 Methods for modulating angiogenesis by using the anti-angiogenic angiotensin-7 and polynucleotides encoding therefor |
| 01/11/2001 | WO2001002431A1 Recombinant adenovirus |
| 01/11/2001 | WO2001002423A2 2'-guanidinyl-substituted oligonucleotides and gene expression modulation therewith |
| 01/11/2001 | WO2001002020A2 Compositions and methods for targeted enzymatic release of cell regulatory compounds |
| 01/11/2001 | WO2001002019A2 Control of gene expression |
| 01/11/2001 | WO2001001998A2 Treatment of endometriosis with antileukoprotease |
| 01/11/2001 | WO2000066739A3 Chlamydia antigens and corresponding dna fragments and uses thereof |
| 01/11/2001 | WO2000066604A3 L-ribo-lna analogues |
| 01/11/2001 | WO2000063364A3 Methods and compositions for inhibiting the function of polynucleotide sequences |
| 01/11/2001 | WO2000061747A3 Clasp-2 transmembrane proteins |
| 01/11/2001 | WO2000061543A3 Esters of l-carnitine or alkanoyl l-carnitines |
| 01/11/2001 | WO2000056351A3 Combination use of gemcitabine and tumor suppressor gene therapy in the treatment of neoplasms |
| 01/11/2001 | WO2000054731A3 Syndesmos and uses thereof |
| 01/11/2001 | WO2000053748A3 Casb618 polynucleotides and polypeptides and their use |
| 01/11/2001 | WO2000053216A3 Use of casb616 polypeptides and polynucleotides for cancer treatment |
| 01/11/2001 | WO2000047622A3 Peptides with anti-angiogenic activity |
| 01/11/2001 | WO2000040273A8 Treatment of viral diseases using an interferon omega expressing polynucleotide |
| 01/11/2001 | WO2000039278A8 Pth functional domain conjugate peptides, derivatives thereof and novel tethered ligand-receptor molecules |
| 01/11/2001 | WO2000029012A8 Methods of alleviating cancer symptoms |
| 01/11/2001 | DE19931883A1 DNA kodierend für Beta-Tubulin und deren Verwendung DNA coding for beta-tubulin, and the use thereof |
| 01/11/2001 | DE19929887A1 cDNA-Sequenzen von zwei Interakoren FANCIP2 und FANCIP3 des Fanconi-Anämie-Proteins der Komplementationsgruppe A cDNA sequences of two Interakoren FANCIP2 and FANCIP3 of the Fanconi anemia complementation group A-protein of the |
| 01/11/2001 | CA2383943A1 Snail, a new marker for tumour invasion and target protein of new antitumoral compounds |
| 01/11/2001 | CA2380875A1 Cell death related drug targets in yeast and fungi |
| 01/11/2001 | CA2378539A1 Adenovirus carrying gag gene hiv vaccine |
| 01/11/2001 | CA2378324A1 Recombinant adenovirus |
| 01/11/2001 | CA2378153A1 Global regulators of bacterial pathogenic genes; bacterial autoinducer inactivation protein, as targets for engineering disease resistance |
| 01/11/2001 | CA2377932A1 Control of gene expression in eukaryotic cells |
| 01/11/2001 | CA2377931A1 Novel mammalian calcium channels and related probes, cell lines and methods |
| 01/11/2001 | CA2377929A1 Dna binding protein and sequence as insulators having specific enhancer blocking activity for regulation of gene expression |
| 01/11/2001 | CA2377795A1 Use of the krit1 gene in angiogenesis |
| 01/11/2001 | CA2377788A1 Methods for modulating angiogenesis by using the anti-angiogenic angiotensin-7 and polynucleotides encoding therefor |
| 01/11/2001 | CA2377784A1 Novel genes and their use in the modulation of obesity, diabetes and energy imbalance |
| 01/11/2001 | CA2377780A1 Compositions and methods for enhanced sensitivity and specificity of nucleic acid synthesis |
| 01/11/2001 | CA2377381A1 Neovascular-targeted immunoconjugates |
| 01/11/2001 | CA2377107A1 Delivery of trefoil peptides |
| 01/11/2001 | CA2376166A1 Control of gene expression |
| 01/11/2001 | CA2373352A1 Adenoviral vectors for treating disease |
| 01/11/2001 | CA2372935A1 Novel antifungal agents and fungicides, method for the production thereof and their use |
| 01/10/2001 | EP1067194A1 Vectors containing a gene coding for CD40 and/or CD40L under the control of a cytokine-inducible promoter which is a human acute phase amyloid A gene promoter. Methods for their production and uses thereof |
| 01/10/2001 | EP1067190A1 Gene therapy for enhancing and/or inducing angiogenesis |
| 01/10/2001 | EP1067188A1 Infection with chimaeric adenoviruses of cells negative for the adenovirus serotype 5 Coxsacki adenovirus receptor (CAR) |
| 01/10/2001 | EP1066396A1 Nucleic acid transfer vectors, compositions containing same and uses |
| 01/10/2001 | EP1066395A1 Inducible alphaviral gene expression system |
| 01/10/2001 | EP1066379A1 Protein variant of the net1 locus |
| 01/10/2001 | EP1066377A1 Methods for prevention and treatment of cancer |
| 01/10/2001 | EP1066327A2 Expression of fusion proteins |
| 01/10/2001 | EP1066323A1 Treatment and prevention of vascular disease |
| 01/10/2001 | EP1066319A1 Production methods and uses of a retrovirus |
| 01/10/2001 | EP1066318A1 Nucleic acid molecules which code proteins influencing bone development |
| 01/10/2001 | EP1066221A2 Vectors and viruses used in gene therapy |
| 01/10/2001 | EP1066061A1 Use of scatter factor to enhance angiogenesis |
| 01/10/2001 | EP1066060A2 Mesenchymal stem cells as immunosuppressants |
| 01/10/2001 | EP1066055A1 Adjuvant-containing vaccines |
| 01/10/2001 | EP1066047A1 Methods and materials for treating inflammatory diseases |
| 01/10/2001 | EP1066028A2 Methods and devices for modulating the immune response |
| 01/10/2001 | EP0862439A4 Ligands to enhance cellular uptake of biomolecules |
| 01/10/2001 | CN1279723A Retroviral vectors comprising a functional splice donor site and a functional splice acceptor site |
| 01/10/2001 | CN1279689A Vitamin D receptor related polypeptides, nucleic acid sequence encoding the same and uses thereof |
| 01/10/2001 | CN1279687A Bi-and tri-cyclic nucleoside, nucleotide and oligonucleotide analoguse |
| 01/09/2001 | US6172212 Pea3 is a tumor suppressor |
| 01/09/2001 | US6172211 Nucleotide sequences which codes a protein that modulates tumor propagation; for the treatment of cancer; antitumor agents; anticarcinogenic agents; antiproliferative agents |
| 01/09/2001 | US6172210 Nucleotide sequences which code enzymatic protein associated with phosphatides; for reduction and prevention of fibrin coagulation and vascular thrombosis; for diagnosing coagulation defects |
| 01/09/2001 | US6172201 Cellular receptor for HIV-1 Vpr essential for G2/M phase |
| 01/09/2001 | US6172194 ARF-p19, a novel regulator of the mammalian cell cycle |
| 01/09/2001 | US6172192 Polypeptide or peptide associated microorganism infection; for diagnosis and prevention protozoan infection of mammals |
| 01/09/2001 | US6172190 Enzymatic polypeptide associated with apoptosis; for treatment of defects in apoptosis; for detection of modulators of apoptosis |
| 01/09/2001 | US6172187 Mammalian polypeptide associated with immune response; for the modulation of apoptosis |
| 01/09/2001 | US6172049 Supplying macromolecules to cells |
| 01/09/2001 | US6172048 Composition containing nucleic acids, preparation and uses |
| 01/09/2001 | US6172047 Therapy for nervous system tumors |
| 01/09/2001 | US6171862 Adding vsv-g protein and polybrene to nucleic acid-lipid complex; genetic engineering |
| 01/09/2001 | US6171861 Recombinational cloning using engineered recombination sites |
| 01/09/2001 | US6171860 Oligonucleotides which target untranslated regions and start codons to prevent transcription of a gene; for treatment of bone disorders, inflammation and cancer; antiinflammatory agents; anticarcinogenic agents; antitumor agents |
| 01/09/2001 | US6171855 Adenoviral expression cassettes which express heterologous gene products; for gene therapy |
| 01/09/2001 | US6171840 LacC from streptococcus pneumoniae |
| 01/09/2001 | US6171838 ratB |
| 01/09/2001 | US6171837 Mouse and human 9-cis-retinol dehydrogenase |
| 01/09/2001 | US6171820 Saturation mutagenesis in directed evolution |
| 01/09/2001 | US6171818 Amino acid sequence of polypeptide from aplysia punctata, a sea snail; for recombinant production of anticarcinogenic agents |
| 01/09/2001 | US6171798 Diagnosing cancer or determining p53 status in a sample by comparing level of expression of specific genes to control; lower level indicates cancer |
| 01/09/2001 | US6171795 Nucleic acid ligands to CD40ligand |
| 01/09/2001 | US6171781 NF-AT polypeptides and polynucleotides |
| 01/09/2001 | US6171612 Gene therapy |
| 01/09/2001 | US6171598 GTP cyclohydrolase II (RIBA) |
| 01/09/2001 | US6171597 Adeno-associated virus vector for boosting immunogenicity of freshly isolated tumor cells |
| 01/04/2001 | WO2001000881A1 Antisense modulation of pi3k p85 expression |
| 01/04/2001 | WO2001000880A2 Diagnostics and therapeutics for diseases associated with an il-1 inflammatory haplotype |
| 01/04/2001 | WO2001000879A1 Novel kinases and uses thereof |
| 01/04/2001 | WO2001000874A2 Cancer associated antigens and uses therefor |